SG/CALL/ELI LILLY & CO/350/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 01:20:58 15/06/2024 am IST | ||
| 49.28 EUR | -0.24% |
|
| Current month | +15.03% | ||
| 1 month | +29.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 49.28 | -0.24% |
| 13/24/13 | 49.4 | +3.28% |
| 12/24/12 | 47.83 | -0.77% |
| 11/24/11 | 48.2 | +0.25% |
| 10/24/10 | 48.08 | +3.64% |
Delayed Quote Deutsche Boerse AG
Last update June 15, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ4FHA |
| ISIN | DE000SQ4FHA5 |
| Date issued | 16/11/2022 |
| Strike | 350 $ |
| Maturity | 21/06/2024 (5 Days) |
| Parity | 10 : 1 |
| Emission price | 7.49 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50.31 € |
|---|---|
| Lowest since issue | 3.3 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
